Currently, the role of IFN-α pathway in SjS pathogenesis has long been clearly defined, and therapies targeting IFN-α may be a candidate treatment strategy for SjS (38–40). The gene discussed is IFNA1; the disease is Schwartz-Jampel syndrome.